CN116348465B - 稠合双环raf抑制剂的手性合成 - Google Patents

稠合双环raf抑制剂的手性合成

Info

Publication number
CN116348465B
CN116348465B CN202180064843.6A CN202180064843A CN116348465B CN 116348465 B CN116348465 B CN 116348465B CN 202180064843 A CN202180064843 A CN 202180064843A CN 116348465 B CN116348465 B CN 116348465B
Authority
CN
China
Prior art keywords
compound
formula
reaction
chiral
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180064843.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN116348465A (zh
Inventor
A·贝尔菲尔德
N·霍金斯
S·C·格洛索普
J-F·玛格特
C·D·琼斯
C·科莱托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Ireland Ltd
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of CN116348465A publication Critical patent/CN116348465A/zh
Application granted granted Critical
Publication of CN116348465B publication Critical patent/CN116348465B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/821—Ruthenium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180064843.6A 2020-07-28 2021-07-28 稠合双环raf抑制剂的手性合成 Active CN116348465B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063057531P 2020-07-28 2020-07-28
US63/057531 2020-07-28
PCT/EP2021/071219 WO2022023450A1 (en) 2020-07-28 2021-07-28 Chiral synthesis of fused bicyclic raf inhibitors

Publications (2)

Publication Number Publication Date
CN116348465A CN116348465A (zh) 2023-06-27
CN116348465B true CN116348465B (zh) 2026-04-17

Family

ID=77564067

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180064843.6A Active CN116348465B (zh) 2020-07-28 2021-07-28 稠合双环raf抑制剂的手性合成

Country Status (10)

Country Link
US (2) US20220041595A1 (https=)
EP (1) EP4188923A1 (https=)
JP (1) JP7832924B2 (https=)
KR (1) KR20230058630A (https=)
CN (1) CN116348465B (https=)
AU (1) AU2021318923A1 (https=)
CA (1) CA3187393A1 (https=)
IL (1) IL300110A (https=)
MX (1) MX2023001274A (https=)
WO (1) WO2022023450A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535790A (ja) 2020-07-28 2023-08-21 ジャズ ファーマシューティカルズ アイルランド リミテッド 縮合二環式ｒａｆ阻害薬及びその使用方法
CN114921508B (zh) * 2022-07-22 2022-10-11 常熟药明康德新药开发有限公司 (r)-6-羟基色满-3-羧酸的生物催化制备方法
JP2025539426A (ja) 2022-11-29 2025-12-05 ジャズ ファーマシューティカルズ アイルランド リミテッド （ｓ）－５－（（３－（４－（４－フルオロフェニル）－１ｈ－イミダゾール－２－イル）クロマン－６－イル）オキシ）－３，４－ジヒドロ－１，８－ナフチリジン－２（１ｈ）－オンの結晶形態
EP4665725A2 (en) * 2023-02-17 2025-12-24 Jazz Pharmaceuticals Ireland Limited Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108588A (zh) * 2014-09-12 2017-08-29 莱德克斯制药公共有限公司 可用于治疗癌症的稠合双环(杂)芳香族化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932657A (en) 1973-11-12 1976-01-13 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome encapsulation of chelating agents
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
JPS6058915A (ja) 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4830858A (en) 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPH0617309B2 (ja) 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
DE3611229A1 (de) 1986-04-04 1987-10-08 Basf Ag Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinoidpraeparaten
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
DE69529054T2 (de) 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US8137699B2 (en) 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2462376C (en) 2001-10-03 2010-12-14 Celator Technologies Inc. Liposome loading with metal ions
CA2467064C (en) 2001-11-13 2011-02-08 Murray Webb Lipid carrier compositions with enhanced blood stability
LT2653465T (lt) * 2004-03-15 2016-09-12 Janssen Pharmaceutica Nv Opioidinio receptoriaus moduliatoriai
JP5001263B2 (ja) * 2005-05-20 2012-08-15 ドクター レディズ ラボラトリーズ （イーユー） リミテッド ジフェニルアラニン誘導体作製のための不斉水素化
CN109503659B (zh) * 2019-01-03 2021-06-18 凯特立斯（深圳）科技有限公司 氧杂螺环双膦配体及其在α,β-不饱和羧酸不对称氢化中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108588A (zh) * 2014-09-12 2017-08-29 莱德克斯制药公共有限公司 可用于治疗癌症的稠合双环(杂)芳香族化合物

Also Published As

Publication number Publication date
EP4188923A1 (en) 2023-06-07
KR20230058630A (ko) 2023-05-03
CN116348465A (zh) 2023-06-27
CA3187393A1 (en) 2022-02-03
WO2022023450A1 (en) 2022-02-03
JP2023535595A (ja) 2023-08-18
JP7832924B2 (ja) 2026-03-18
MX2023001274A (es) 2023-04-24
US20220041595A1 (en) 2022-02-10
AU2021318923A1 (en) 2023-03-09
IL300110A (en) 2023-03-01
US20260049079A1 (en) 2026-02-19

Similar Documents

Publication Publication Date Title
CN116348465B (zh) 稠合双环raf抑制剂的手性合成
KR101749192B1 (ko) 트리아진, 피리미딘 및 피리딘 유사체 및 이의 치료제 및 진단 프로브로의 용도
US7566716B2 (en) Imidazopyrazines as Raf inhibitor compounds
TWI642667B (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
AU2024253142A1 (en) Pyrido[4,3-d]pyrimidine compounds
CA2778291C (en) Akt inhibitors
JP6307096B2 (ja) 化合物
CN101282960A (zh) Raf抑制剂化合物和方法
AU2015314007A1 (en) Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
US12304912B2 (en) Fused bicyclic RAF inhibitors and methods for use thereof
WO2019120194A1 (zh) 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途
JP2021528413A (ja) Ｏｇａ阻害化合物
RU2846441C1 (ru) Хиральный синтез конденсированных бициклических ингибиторов raf
JP2025541854A (ja) カンプトテシン誘導体、医薬組成物及びその製造方法と使用
KR20170095243A (ko) Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체
JP2024501658A (ja) 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
CA3122128C (en) Kinase inhibitor Pan-Kit with a quinoline structure and its use
WO2025101588A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
RU2792626C1 (ru) Новый ингибитор киназы pan-raf и его применение
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
BR112016025153B1 (pt) "compostos de imidazo[4,5-c]quinolin-2-ona, composição farmaceutica e seu uso no tratamento de câncer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant